Global Malaria Vaccines Market: Overview
The prevalence of malaria in tropical countries has been troublesome to the entire world, contributing to millions of deaths over the last ten years. Vaccine development forms a crucial part of adequate interventional control. Recent years have seen considerable research on novel vaccine candidates. Supported by continuous research of malaria life-cycle, a diverse pipeline has been investigated. Understanding the biology of deadly human malaria parasites Plasmodium falciparum and Plasmodium vivax is key to growing avenues in the malaria vaccines market. Generations of pre-erythrocytic vaccines have unlocked new avenues in the malaria vaccines market. This has attracted a volley of investments from biotech companies. RTS,S/AS01 (RTS,S) is the most vigorously tested vaccine candidate for prevention of malaria caused by P. falciparum.
The study on the global malaria vaccines market takes a closer look at the investment trends related with different approached of vaccine development around the world. It provides a scrutiny on the efforts of healthcare systems to reduce the burden of malaria, especially in countries where it has grown to endemic proportions. It highlights key growth drivers and challenges to various stakeholders in vaccine development during the forecast period (2019 – 2027).
Global Malaria Vaccines Market: Key Trends
The report on the malaria vaccine market provides a granular assessment of key growth avenues for vaccine manufacturers, share and size of various segments, and projections of opportunities in these during the forecast period of 2019 – 2027. It takes a closer look at clinical testing of next-generation vaccine designs.
Over the past couple of years, researchers have been able to increase the vaccine-induced efficacy considerably. Spate of clinical trials have focused on improving RTS,S/AS01. Such developments were invigorated by recent trials sub-Saharan Africa. According to the WHO, RTS,S has been evaluated for use as a complementary malaria control tool to its preventive, diagnostic, and treatment measures. It is the only vaccine that has demonstrated its efficacy in reducing malaria, especially in young African children.
The growing number of routine immunization programs in various countries is boosting the malaria vaccines market. Over the past few years, The WHO has made coordinated efforts to promote public health use of the vaccine. The advent of novel adjuvants and cutting-edge vaccine delivery platforms are opening new avenues in the malaria vaccine market.
Global Malaria Vaccines Market: Geographical Analysis
Growing funding on vaccine development programs have made developed regions center of attention for players in malaria vaccines market. In this regard, the prospects in the malaria vaccines market are bolstered by a positive outlook of regulatory authorities in Europe. Growing number of phase 2 and 3 trials have seen lucrative avenues for vaccine manufacturers in Africa. Latin America has also seen the rapidly growing number of malaria cases. Further, North America is projected to be one of the most prominent regional markets. Asia Pacific is expected to be one of the promising regions for vaccine development.
Global Malaria Vaccines Market: Competitive Scenario
Key markets have scientists utilizing malaria research platforms. Pharmaceutical companies in these markets have made an array of recent investments. Companies who intend to put large stakes in the malaria vaccines market are carefully considering immunological and genetic considerations. New entrants are more likely to lay increased focus on cost-effectiveness of the recent vaccine candidates. Some of the well-entrenched players in the malaria vaccines market are Genome ReS Ltd., VLP Therapeutics LLC, Cadila Healthcare Ltd., CellFree Sciences Co. Ltd., Sanaria, GenVec, Inc., Nobelpharma, and GlaxoSmithKline.
Disclaimer: This ongoing market research study is a meticulously planned activity where a broad array of factors and aspects that shape the marketing environment and industry are taken into account. However, keeping in mind the constantly changing nature of business dynamics and changing strategic intents, we are always actively making iterations and modifications in our approaches. As always, we are ready to tailor our insights and guidance to suit your requirements. Engage with us to know what more is there for your CXOs.